Segment Reporting (Details) - USD ($) |
12 Months Ended | |
|---|---|---|
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Segment Reporting [Abstract] | ||
| Clinical studies | $ 3,660,000 | $ 11,081,000 |
| Clinical teams | 4,479,000 | 8,873,000 |
| Other research and development expenses | 294,000 | 1,081,000 |
| Selling, general and administrative expenses | 8,570,000 | 8,850,000 |
| Amortization of intangible assets | 229,000 | 229,000 |
| Other income, net | (524,000) | (59,000) |
| Net loss | $ (17,542,000) | $ (32,121,000) |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue and income classified as other. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|